| Title |
A phase Ib/II study of ivonescimab, a PD-1/VEGF bispecific antibody,as first- or second-line therapy for advanced non-small-cell lungcancer |
| Description |
Ivonescimab, a bispecific antibody against programmed death-1 (PD-1) and vascular endothelial growth factor (VEGF),showed preliminary antitumor activity and a favorable toxicity profile in early phase trials on solid tumors. This study aimed to evaluate the safety and efficacy of ivonescimab monotherapy as first- or second-line therapy in advanced non-small-cell lung cancer (NSCLC) patients. |
| Organism |
Homo sapiens |
| Data Type |
Biomarker Data |
| Data Accessibility |
Controlled-access |
| BioProject |
PRJCA015969 |
| Release Date |
2024-12-31 |
| Submitter |
ling zhang (shfkgcp@163.com) |
| Organization |
shanghai pulmonary hospital |
| Submission Date |
2023-03-31 |